Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)

INTRODUCTION: Osimertinib is an effective therapy in EGFR mutant NSCLC, but resistance invariably develops. Navitoclax is an oral inhibitor of BCL-2/BCL-xL that has exhibited synergy with osimertinib in preclinical models of EGFR-mutant NSCLC. In hematologic malignancies, BCL-2 family inhibitors in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Bertino, Erin M., Gentzler, Ryan D., Clifford, Sarah, Kolesar, Jill, Muzikansky, Alona, Haura, Eric B., Piotrowska, Zofia, Camidge, D. Ross, Stinchcombe, Thomas E., Hann, Christine, Malhotra, Jyoti, Villaruz, Liza C., Paweletz, Cloud P., Lau, Christie L., Sholl, Lynette, Takebe, Naoko, Moscow, Jeffrey A., Shapiro, Geoffrey I., Jänne, Pasi A., Oxnard, Geoffrey R.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7976451/
https://ncbi.nlm.nih.gov/pubmed/33376097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4084
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars